Cargando…
Difference in cytokine production and cell cycle progression induced by Epstein-Barr virus Lmp1 deletion variants in Kmh2, a Hodgkin lymphoma cell line
BACKGROUND: Epstein-Barr virus (EBV) is associated with 20-40% of Hodgkin’s Lymphoma (HL) cases. EBV-encoded latent membrane protein 1 (LMP1) is a well-known oncogenic protein and two C-terminal deletion variants, del30-LMP1 and del69-LMP1, have been described in animal models to be more tumorigenic...
Autores principales: | Sueur, Charlotte, Lupo, Julien, Mas, Philippe, Morand, Patrice, Boyer, Véronique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035821/ https://www.ncbi.nlm.nih.gov/pubmed/24886620 http://dx.doi.org/10.1186/1743-422X-11-94 |
Ejemplares similares
-
The Role of Epstein-Barr Virus LMP-1 Immunohistochemical Staining in Childhood Hodgkin Lymphoma
por: Tanyildiz, Hikmet Gulsah, et al.
Publicado: (2015) -
Virological Markers in Epstein–Barr Virus-Associated Diseases
por: Lupo, Julien, et al.
Publicado: (2023) -
Loss of P16 Protein Expression and Its Association with Epstein-Barr Virus LMP-1 Expression in Hodgkin's Lymphoma
por: Irshaid, Fawzi, et al.
Publicado: (2013) -
Transcriptome Changes Induced by Epstein-Barr Virus LMP1 and LMP2A in Transgenic Lymphocytes and Lymphoma
por: Shair, Kathy H. Y., et al.
Publicado: (2012) -
Main Targets of Interest for the Development of a Prophylactic or Therapeutic Epstein-Barr Virus Vaccine
por: Jean-Pierre, Vincent, et al.
Publicado: (2021)